The Vaccine Company Report issue

For profit Phase 2 Phase 3
Founded: South San Francisco CA United States (2003)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2005
NCT00454168
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6